Abstract
Most of the poliovirus vaccine distributed in the United States since 1962 has been of the live, oral type ( OPV ). Production problems have not been a major concern for the manufacturer. The statistics compiled by various authorities since the product was introduced relative to paralytic disease following the administration of OPV are discussed and recommendations for the use of OPV are cited.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
